Introduction: The world has experienced an outbreak of coronavirus disease (COVID-19), caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The middle east countries were hit like the rest of the world with this pandemic. Hypothesis: In-hospital mortality has been reported in many countries, but similar reports from middle eastern countries have not been well described. Methods: In this retrospective, multicentre cohort study, we included all adult hospitalized in the intensive care Unit with laboratory-confirmed COVID-19 in the two main hospitals in Oman, Sultan Qaboos University Hospital SQUH and Royal Hospital RH between the period of 1 st of March to May 30 th , 2020. Demographic, clinical presentation, treatment and outcome, were extracted from electronic medical records and compared between survivors and non-survivors. We used univariable and multivariable logistic regression methods to explore the risk factors associated with in-hospital death. Findings: 153 patients admitted in ICU ,60 from SQUH and 93 from RH were included in this study, of whom 131 (85.6%) were discharged and 22 (14.3%) died in hospital. The mean age of the patients was 49.56±15.20. Males were accounted 126 (83.4%) and females were 25 (16.6%). Nearly 40% of them were Omani citizens and rest of 60% were residents of Oman. Those who have history of coronary artery disease found to have higher in hospital mortality rate OR= 4.09, 95% C.I 1.57-10.6) in which mortality in patients on aspirin was (31.8% in non-survival group vs 10.8% in survival group, p=0.047), clopedogril (18.2% vs 2.3%, p=0.009) and statin (31.8% vs 10.6%, p=0.016)At presentation, non-survivals were found to have significantly higher troponin with the risk of 7.07 (C.I. 2.09-23.92. p=0.002). In fact, patients with high sensitivity troponin rise >100 ng/L were more likely to die 5.83 times than the group with troponin 100ng/L was independent risk factors for death of COVID-19. Identifying these risk factors could help to assess the prognosis of these patients at early stage.